[{"id":"14e3df84-b533-4173-b75c-16ee69ed3716","acronym":"","url":"https://clinicaltrials.gov/study/NCT06114511","created_at":"2023-11-02T15:12:55.772Z","updated_at":"2024-07-02T16:35:03.825Z","phase":"Phase 1/2","brief_title":"A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer","source_id_and_acronym":"NCT06114511","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab brengitecan (BL-M07D1)"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 04/24/2024","start_date":" 04/24/2024","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-05-14"},{"id":"03bc5e50-b478-4d68-87f2-dc93e0cc73f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06031584","created_at":"2023-09-11T16:10:34.582Z","updated_at":"2024-07-02T16:35:15.514Z","phase":"Phase 1/2","brief_title":"A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors","source_id_and_acronym":"NCT06031584","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression • HER-2 underexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression • HER-2 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab brengitecan (BL-M07D1)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 01/19/2024","start_date":" 01/19/2024","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-03-08"},{"id":"36b29921-69ba-4692-a12f-cfab56282a8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05631964","created_at":"2022-11-30T17:57:35.726Z","updated_at":"2024-07-02T16:35:21.539Z","phase":"Phase 1","brief_title":"Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors","source_id_and_acronym":"NCT05631964","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab brengitecan (BL-M07D1)"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 01/05/2023","start_date":" 01/05/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-01-31"},{"id":"c470b529-9dfd-48a9-8efd-1f3df1255e9b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05461768","created_at":"2022-07-18T14:01:36.397Z","updated_at":"2024-07-02T16:35:21.563Z","phase":"Phase 1","brief_title":"A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors","source_id_and_acronym":"NCT05461768","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression • HER-2 underexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression • HER-2 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab brengitecan (BL-M07D1)"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 08/09/2022","start_date":" 08/09/2022","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-01-31"}]